AI tool to predict gene mutations in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an AI tool called DeepGEM that predicts gene mutations (EGFR, ALK, ROS1) from lung cancer tissue slides. If you have non-small cell lung cancer and haven't had treatment yet, this study may help guide your therapy without needing extra biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have non-small cell lung cancer (NSCLC) that has spread (stage II to IV)
- Your doctors have a good-quality digital image of your tumor tissue
- The AI tool successfully finds mutations in EGFR, ALK, or ROS1 genes
- You have never received chemotherapy, targeted therapy, or immunotherapy for your cancer
- You are willing to follow the study plan and give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This trial uses artificial intelligence (AI) to analyze your medical images, genetic tests, and pathology reports to see how well targeted therapy (EGFR-TKI) works after lung cancer surgery. It may help doctors better predict treatment outcomes.
Hear when a new Non Small Cell Lung Caner trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.